IP Verse

Allergan, Inc. opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Allergan, Inc.

Patent Number:
EP3236939
Title:
Botulinum Toxin Prefilled Container
Applicant:
MERZ PHARMA GMBH & CO. KGAA
Opposition Date:
Dec 31, 2020
Patent Number:
EP3233043
Title:
Process For Preparing Hydrogels
Applicant:
TEOXANE
Opposition Date:
Aug 5, 2020
Patent Number:
EP3274685
Title:
Process For Evaluating The Mechanical Performance Of A Filler Gel
Applicant:
TEOXANE
Opposition Date:
Jul 2, 2020
Patent Number:
EP3027186
Title:
Composition Comprising Hyaluronic Acid And Mepivacaine
Applicant:
TEOXANE
Opposition Date:
Mar 18, 2020
Patent Number:
EP2912074
Title:
Dermal Injectable Sterile Composition
Applicant:
TEOXANE
Opposition Date:
Feb 3, 2020
Patent Number:
EP2939688
Title:
Pharmaceutical Compositions Comprising Botulinum Neurotoxin
Applicant:
IPSEN BIOPHARM LIMITED
Opposition Date:
Nov 20, 2019
Patent Number:
EP3250185
Title:
Ophthalmic Suspension Composition
Applicant:
BAUSCH & LOMB INCORPORATED
Opposition Date:
Sep 4, 2019
Patent Number:
EP2627318
Title:
Formulation Suitable For Stabilizing Proteins, Which Is Free Of Mammalian Excipients
Applicant:
MERZ PHARMA GMBH & CO. KGAA
Opposition Date:
May 16, 2018
Patent Number:
EP2661276
Title:
Methods And Kits For Topical Application, Removal, And Inactivation Of Therapeutic Or Cosmetic Toxin Compositions
Applicant:
REVANCE THERAPEUTICS, INC.
Opposition Date:
May 2, 2018
Patent Number:
EP2677029
Title:
Methods For The Manufacture Of Proteolytically Processed Polypeptides
Applicant:
IPSEN BIOINNOVATION LIMITED
Opposition Date:
Feb 9, 2018

Latest patents of Allergan, Inc. opposed by its competitors

Patent:
EP2877138
Grant Date:
Jun 28, 2023
Title:
Dual Cap System For Container-Closures To Maintain Tip Sterility During Shelf Storage
Oppositions:
1
Patent:
EP2381923
Grant Date:
Jun 7, 2023
Title:
Safe Desmopressin Administration
Oppositions:
1
Patent:
EP3436054
Grant Date:
Jul 27, 2022
Title:
Stabilized Non-Protein Clostridial Toxin Compositions
Oppositions:
1
Patent:
EP3520827
Grant Date:
May 25, 2022
Title:
Cross-Linked Hydrogels For Soft Tissue Augmentation
Oppositions:
1
Patent:
EP3681500
Grant Date:
Mar 23, 2022
Title:
Use Of Pilocarpine Hydrochloride For The Treatment Of Ocular Conditions
Oppositions:
1
Patent:
EP3431074
Grant Date:
Jan 19, 2022
Title:
Preservative Free Bimatoprost And Timolol Solutions
Oppositions:
6
Patent:
EP3279335
Grant Date:
Mar 10, 2021
Title:
Highly Sensitive Cell-Based Assay To Detect The Presence Of Active Botulinum Neurotoxin Serotype-A
Oppositions:
1
Patent:
EP3169308
Grant Date:
Jan 27, 2021
Title:
Suspension Compositions Of Cyclosporin A For Subconjunctival And Periocular Injection
Oppositions:
1
Patent:
EP3068403
Grant Date:
Jun 17, 2020
Title:
Methods Of Treatment Of Ocular Conditions With A Sustained Drug Delivery Implant
Oppositions:
1
Patent:
EP3187219
Grant Date:
Apr 22, 2020
Title:
Injection Device
Oppositions:
1

Competitors of Allergan, Inc.

MERZ PHARMA GMBH & CO. KGAA

TEOXANE

FERRING B.V.

Want to track Allergan, Inc.?

Feel free to send us a message here and we will get back to you